Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver Mutations

Inclusion Criteria: * Age ≥18 years. * Histologically or cytologically confirmed stage III NSCLC (AJCC 8th edition), considered resectable or potentially resectable. * Documented EGFR exon 20 insertion, ALK fusion, ROS1 fusion, MET exon 14 skipping alteration, RET fusion, or KRAS G12C mutation. * At least one measurable lesion per RECIST 1.1 and ECOG performance status 0-1. * Adequate cardiopulmonary and major organ function for surgery. * Written informed consent and willingness to comply with study procedures, sample collection, and follow-up. Exclusion Criteria: * Stage III NSCLC considered unresectable by surgical assessment. * Lung cancer treatment within the previous 2 years, or prior lung cancer with a remission duration of less than 2 years. * Another malignancy within the previous 5 years. * Major surgery within 28 days before the first study dose. * Any contraindication to the assigned targeted therapy. * Inability or unwillingness to provide informed consent or comply with study requirements.